<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28915" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Seronegative Spondyloarthropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sen</surname>
            <given-names>Rouhin</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hurley</surname>
            <given-names>John A.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rouhin Sen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Hurley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28915.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Seronegative spondyloarthropathies are a family of joint disorders that classically include ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD) associated arthritis, reactive arthritis (formerly Reiter syndrome; ReA), and undifferentiated SpA. Patients with seronegative spondyloarthropathy often present with inflammatory joint pain characterized by morning stiffness lasting more than one hour and improving with activity. NSAIDs may improve symptoms. This activity illustrates the evaluation and treatment of seronegative spondyloarthropathies and reviews the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of seronegative spondyloarthropathy.</p></list-item><list-item><p>Review the presentation of a patient with seronegative spondyloarthropathy.</p></list-item><list-item><p>Summarize the treatment options for seronegative spondyloarthropathy.</p></list-item><list-item><p>Outline the importance of collaboration and communication among the interprofessional team members in reducing functional limitations, reducing symptoms, and decreasing complication which will improve outcomes for those with this disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28915&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28915">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28915.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Seronegative spondyloarthropathies (SpA) are a family of rheumatologic disorders that classically include<xref ref-type="bibr" rid="article-28915.r1">[1]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Ankylosing spondylitis (AS)</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis (PsA)</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease (IBD) associated arthritis</p>
          </list-item>
          <list-item>
            <p>Reactive arthritis (formerly Reiter syndrome; ReA)</p>
          </list-item>
          <list-item>
            <p>Undifferentiated SpA.&#x000a0;</p>
          </list-item>
        </list>
        <p>Recently, these disorders have been differentiated&#x000a0;further&#x000a0;into three additional categories including non-radiographic axial SpA (nr-axSpA), peripheral SpA, and lastly, juvenile-onset SpA. This family of disorders shares several clinical features and has common genetic associations.</p>
      </sec>
      <sec id="article-28915.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There is a classic correlation between the prevalence of SpA and the prevalence of <italic toggle="yes">HLA-B27</italic> gene in a given population. The strongest relationship is in AS. In the United States, the prevalence of<italic toggle="yes"> HLA-B27</italic> is 7% of the general population, but it is present in 90% of those diagnosed with AS<xref ref-type="bibr" rid="article-28915.r2">[2]</xref><xref ref-type="bibr" rid="article-28915.r3">[3]</xref>. PsA is associated with multiple HLA molecules including <italic toggle="yes">HLA-B27</italic>, <italic toggle="yes">HLA-DR7</italic>, and <italic toggle="yes">HLA-DQ3</italic>. In IBD associated arthritis (Crohn disease and ulcerative colitis), the HLA association is weaker compared to the other SpAs. ReA (which follows enteric or urogenital infection) has a variable relationship with <italic toggle="yes">HLA-B27</italic> with studies reporting anywhere from below 50% to 60% to 85% association<xref ref-type="bibr" rid="article-28915.r4">[4]</xref><xref ref-type="bibr" rid="article-28915.r5">[5]</xref>. <italic toggle="yes">HLA-B27</italic> is positive in about 50% of those with undifferentiated SpA and 60% to 80% of those with juvenile-onset SpA.</p>
      </sec>
      <sec id="article-28915.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The worldwide prevalence of SpA is estimated to be between 0.5% to 1.9%<xref ref-type="bibr" rid="article-28915.r3">[3]</xref>. In the United States, AS and non-radiographic axial SpA are the most common types of SpA and have a combined prevalence of 0.7% to 1.4%<xref ref-type="bibr" rid="article-28915.r2">[2]</xref>. PsA is thought to affect men and women equally with a prevalence of 0.1% to 0.2% and incidence of 0.006%<xref ref-type="bibr" rid="article-28915.r6">[6]</xref>. PsA is thought to be present in 4% to 30% of individuals with psoriasis. IBD-associated arthritis (both axial and peripheral) is present in 3% to 13% of patients with either ulcerative colitis or Crohn disease<xref ref-type="bibr" rid="article-28915.r7">[7]</xref>. ReA is thought to be quite rare. The typical organisms causing ReA are <italic toggle="yes">Chlamydia</italic>, <italic toggle="yes">Campylobacter</italic>,<italic toggle="yes"> Salmonella</italic>,<italic toggle="yes"> Shigella</italic>,<italic toggle="yes"> Clostridium difficile. </italic>Globally, the prevalence is estimated to be 0.03% to 0.04%<xref ref-type="bibr" rid="article-28915.r8">[8]</xref>.</p>
      </sec>
      <sec id="article-28915.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Enthesitis, or inflammation of the sites where the tendons or ligaments insert into the bone, is a key pathological finding in SpA<xref ref-type="bibr" rid="article-28915.r9">[9]</xref>. This&#x000a0;finding differentiates it from rheumatoid arthritis and other inflammatory polyarthritides. As mentioned above, the major gene involved in several key pathogenic steps is<italic toggle="yes"> HLA-B27</italic>. Several non-HLA genes have also been identified in disease pathogenesis. Environmental exposure of the immune system to microorganisms is also important. Several cytokines have been shown to participate in the inflammatory process. One of these cytokines is tumor necrosis factor (TNF) which is a target for a class of drugs used to treat the SpA<xref ref-type="bibr" rid="article-28915.r9">[9]</xref>. It is thought that microtrauma from stress also triggers inflammation at the enthesis<xref ref-type="bibr" rid="article-28915.r10">[10]</xref>. These inflammatory processes lead to change in bone and pathologic new bone formation, which is seen in AS but not in rheumatoid arthritis.</p>
      </sec>
      <sec id="article-28915.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologic studies on synovial fluid show hypervascularity and the presence of macrophages and CD4+ and CD8+ T-cells. Interestingly, some of these same subsets of immune cells are also found in the gut mucosa. Macrophages and macrophage-driven cytokines such as TNF-alpha and IL10 are mediators of disease inflammation<xref ref-type="bibr" rid="article-28915.r11">[11]</xref>.</p>
      </sec>
      <sec id="article-28915.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History should be taken to evaluate for inflammatory back and/or peripheral joint pain. Inflammatory joint pain is associated with morning stiffness lasting more than one&#x000a0;hour, improving&#x000a0;with activity, and worsening with rest or inactivity. NSAIDs may markedly improve symptoms. Patients with axial SpA typically have chronic low back pain for more than three months with insidious onset before the age of 45. In these patients, the Schober&#x02019;s test (for assessment of lumbar flexion) and occiput to wall test (for assessment of upper thoracic/cervical spine mobility) should be a routine part of the physical exam<xref ref-type="bibr" rid="article-28915.r12">[12]</xref>. Those with peripheral SpA have peripheral arthritis (acute onset, usually knees and ankles), enthesitis, and dactylitis. It is important to note that the peripheral arthritis is usually asymmetric. Enthesitis is relatively specific to SpA and is usually seen at the insertion of the calcaneal tendon. This typically leads to difficulty walking and to tenderness upon palpation. Dactylitis is a non-specific finding but is often seen in PsA and ReA. Non-musculoskeletal features that are important to ascertain in the history include ocular inflammation (uveitis, iritis, conjunctivitis), preceding/current gastrointestinal or genitourinary (GI/GU) infection, or diagnosis of or signs of psoriasis or IBD. Lastly, family history of SpA and other autoimmune disorders should be assessed.</p>
      </sec>
      <sec id="article-28915.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of SpA involves both laboratory and radiographic testing. The approach differs depending on whether a patient presents with inflammatory back pain vs. inflammatory arthritis, enthesitis, or dactylitis.</p>
        <p>In a patient who presents with inflammatory back pain, the initial step is to obtain plain films of the sacroiliac joints and spine as well as inflammatory markers. Inflammatory markers should be elevated in the presence of a SpA. In AS, plain films typically detect late structural changes and may not be useful early in the disease. Classic findings on plain film are 1) &#x0201c;shiny corner (sclerosis at the attachment of annulus fibrosis to the anterior corner of vertebral endplate), 2) &#x0201c;bamboo spine&#x0201d; (calcification of fibrous ring of the intervertebral discs forming marginal syndesmophytes), and 3) &#x0201c;squaring&#x0201d; of vertebral bodies<xref ref-type="bibr" rid="article-28915.r12">[12]</xref>. Typically, if a patient does not have strong plain film evidence of AS, <italic toggle="yes">HLA-B27</italic> is obtained; at that time, MRI can also be considered as it is useful for early detection of signs of inflammation. Patients with nr-axSpA do not have definitive radiographic findings of sacroiliitis but have serological and clinical evidence of a SpA<xref ref-type="bibr" rid="article-28915.r13">[13]</xref>.</p>
        <p>In a patient who presents with signs of inflammatory arthritis, enthesitis, or dactylitis, the presence of psoriasis, IBD, or preceding infection should be evaluated. In the presence of a predisposing condition, a diagnosis of PsA, IBD-related SpA, or ReA can be made. In the absence of a predisposing condition, autoimmune (including <italic toggle="yes">HLA-B27</italic>) and inflammatory markers should be obtained, and patients should have radiographs of their affected joint(s) and be evaluated for uveitis.</p>
      </sec>
      <sec id="article-28915.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment goals for SpA are reducing symptoms, reducing functional limitations, and decreasing complications associated with the disease. A mainstay of therapy is an exercise to preserve spine and peripheral joint strength and range of motion. Often, formal physical therapy is beneficial<xref ref-type="bibr" rid="article-28915.r14">[14]</xref>. The main pharmacologic therapy is&#x000a0;a NSAID, usually in maximal doses (except in IBD associated arthritis), and at least two NSAIDs must be tried&#x000a0;before advancing to the next class of pharmacologic agents<xref ref-type="bibr" rid="article-28915.r15">[15]</xref>. In the event NSAIDs fail to control symptoms, are intolerable due to side effects, or are contraindicated due to other co-morbid conditions, the next step in treatment depends on whether the disease is axial disease or peripheral disease.</p>
        <p>In axial disease (AS), biologics (TNF inhibitors) are the next line of therapy. Five TNF inhibitors, infliximab, etanercept, adalimumab, golimumab, and certolizumab, are shown to achieve partial or full remission of symptoms. Of note, active infection (including latent or active tuberculosis which should be treated before starting treatment), advanced heart failure, lupus, multiple sclerosis, and cancer are contraindications for treatment with TNF inhibitors. Secukinumab, a monoclonal antibody to interleukin 17A, has been recently approved to treat AS and has been shown to be quite effective in those who cannot tolerate TNF inhibitors<xref ref-type="bibr" rid="article-28915.r16">[16]</xref>. Non-biologic DMARDS (disease modifying anti-rheumatic drugs) such as methotrexate and sulfasalazine are not effective in axial disease but are a second-line treatment for the peripheral disease<xref ref-type="bibr" rid="article-28915.r15">[15]</xref>. In the event, the non-biologics do not control disease, TNF-inhibitors are the third line, and at times, combination therapy with both biologic and non-biologic DMARDs is required. Systemic glucocorticoids have a limited role in SpA. For IBD associated arthritis and patients with severe uveitis, they may be unavoidable. Localized glucocorticoid injections should be used very sparingly due to the risk of tendon rupture. It is important to note that although ReA is usually a self-limited disease, it can be treated similarly to any other disease in the SpA family. Surgery is the very last resort management strategy. Disease progression is measured by history, physical exam, inflammatory markers, and serial imaging<xref ref-type="bibr" rid="article-28915.r15">[15]</xref>.</p>
      </sec>
      <sec id="article-28915.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Congenital Spinal Deformity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Degenerative Disk Disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic Foot Ulcers</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Herniated Nucleus Pulposus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Heterotopic Ossification Imaging</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Kyphosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lumbar Disc Disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lumbar Spondylosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Osteoarthritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Osteofibrous Dysplasia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28915.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Seronegative spondyloarthropathy&#x000a0;is difficult to diagnose and treat. An interprofessional&#x000a0;approach of specialty trained rehabilitation nurses, physical therapists, and rehabilitation and rheumatology clinicians will provide the most successful management of this condition. A pharmacist should assist in monitor phramacotherapy. [Level V]</p>
      </sec>
      <sec id="article-28915.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28915&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28915">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/seronegative-spondyloarthropathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28915">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28915/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28915">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28915.s13">
        <title>References</title>
        <ref id="article-28915.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Healy</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Helliwell</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Classification of the spondyloarthropathies.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>395</fpage>
            <page-range>395-9</page-range>
            <pub-id pub-id-type="pmid">15956834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shillington</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Cifaldi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruderman</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>65</volume>
            <issue>8</issue>
            <fpage>1299</fpage>
            <page-range>1299-306</page-range>
            <pub-id pub-id-type="pmid">23436774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakland</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of spondyloarthritis: a review.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>351</fpage>
            <pub-id pub-id-type="pmid">23888360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakland</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alsing</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>448</fpage>
            <page-range>448-53</page-range>
            <pub-id pub-id-type="pmid">22833469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Breban</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lories</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-20</page-range>
            <pub-id pub-id-type="pmid">23288559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shbeeb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uramoto</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.</article-title>
            <source>J Rheumatol</source>
            <year>2000</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1247</fpage>
            <page-range>1247-50</page-range>
            <pub-id pub-id-type="pmid">10813295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karreman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Luime</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hazes</surname>
                <given-names>JMW</given-names>
              </name>
              <name>
                <surname>Weel</surname>
                <given-names>AEAM</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</article-title>
            <source>J Crohns Colitis</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-642</page-range>
            <pub-id pub-id-type="pmid">28453761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leirisalo-Repo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reactive arthritis.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2005</year>
            <season>Jul-Aug</season>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-9</page-range>
            <pub-id pub-id-type="pmid">16195157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kehl</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Corr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>312</fpage>
            <page-range>312-22</page-range>
            <pub-id pub-id-type="pmid">26473401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Mechelen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lories</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Microtrauma: no longer to be ignored in spondyloarthritis?</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-80</page-range>
            <pub-id pub-id-type="pmid">26751839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeten</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Keyser</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The histopathology of spondyloarthropathy.</article-title>
            <source>Curr Mol Med</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">15011954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taurog</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chhabra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colbert</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Ankylosing Spondylitis and Axial Spondyloarthritis.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Sep</month>
            <day>29</day>
            <volume>375</volume>
            <issue>13</issue>
            <fpage>1303</fpage>
            <pub-id pub-id-type="pmid">27682050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory back pain: the United States perspective.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>501</fpage>
            <page-range>501-12</page-range>
            <pub-id pub-id-type="pmid">23083751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoving</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lacaille</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Urquhart</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hannu</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Sluiter</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Frings-Dresen</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Nov</month>
            <day>06</day>
            <volume>2014</volume>
            <issue>11</issue>
            <fpage>CD010208</fpage>
            <pub-id pub-id-type="pmid">25375291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ls</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stamm</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Betteridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>FVD</given-names>
              </name>
              <name>
                <surname>Coates</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Helliwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jongkees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Maccarone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Molto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogdie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poddubnyy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ritchlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thio</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Veale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vlam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-17</page-range>
            <pub-id pub-id-type="pmid">28684559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28915.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Van den Bosch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sepriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Regel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ciurea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dagfinrud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>G&#x000e9;her</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Jongkees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiltz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Marzo-Ortega</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Molto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro-Comp&#x000e0;n</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ozgocmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pimentel-Santos</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Reveille</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rudwaleit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sampaio-Barros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>978</fpage>
            <page-range>978-991</page-range>
            <pub-id pub-id-type="pmid">28087505</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
